|Brand name(s), other common name(s)||Revlimid®|
|How the drug is given||By mouth|
Lenalidomide is FDA approved, in combination with dexamethasone, to treat people with myeloma who have received at least one prior therapy. It is also FDA approved to treat transfusion-dependent anemia in patients with a certain type of myelodysplastic syndrome (MDS) called 5q MDS. Patients with this type of MDS may have low red blood cell counts and require blood transfusions. Lenalidomide is also approved for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (Velcade®).
Side effects needing medical attention: Arm or leg swelling; black, tarry stools; bleeding gums; blood in urine or stools; chest pain; chills; cough; convulsions; decreased urine or painful or difficult urination; difficult or labored breathing, shortness of breath or wheezing; dry mouth; fever; increased thirst; irregular heartbeat; loss of appetite; lower back or side pain; mood changes; muscle pain or cramps; nausea or vomiting; numbness or tingling in hands, feet or lips; pale skin; pinhead-sized red spots on skin; sore throat; sores, ulcers or white spots on lips or in mouth; swollen glands; tightness in chest; unusual bleeding or bruising; unusual tiredness or weakness.